Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269094 | 1.00 | ALDH1A1 (0.39) | ALDH1A1HTTSMN1; SMN2GAARAB9A | |
| SCHEMBL4264176 | 0.88 | CNR1 (0.42) | ALDH1A1SMN1; SMN2GAAKDM4ECNR1 | |
| SCHEMBL4264170 | 0.88 | CNR1 (0.42) | ALDH1A1SMN1; SMN2GAAKDM4ECNR1 | |
| SCHEMBL4263021 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HTTSMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL4263017 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HTTSMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL4263758 | 0.81 | CRHR1 (0.41) | ALDH1A1HTTSMN1; SMN2GAARAB9A | |
| SCHEMBL4263765 | 0.81 | CRHR1 (0.41) | ALDH1A1HTTSMN1; SMN2GAARAB9A | |
| SCHEMBL6459387 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HTTSMN1; SMN2GAARAB9A | |
| SCHEMBL6459383 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HTTSMN1; SMN2GAARAB9A | |
| SCHEMBL4256741 | 0.79 | SMN1; SMN2 (0.36) | ALDH1A1HTTSMN1; SMN2GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | ALDH1A1 765/4885HTT 1365/4885SMN1; SMN2 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.